The stock of X4 Pharmaceuticals Inc (XFOR) has seen a 40.16% increase in the past week, with a -15.68% drop in the past month, and a -24.64% decrease in the past quarter. The volatility ratio for the week is 9.29%, and the volatility levels for the past 30 days are at 16.62% for XFOR. The simple moving average for the past 20 days is 29.47% for XFOR’s stock, with a -35.90% simple moving average for the past 200 days.
Is It Worth Investing in X4 Pharmaceuticals Inc (NASDAQ: XFOR) Right Now?
XFOR has 36-month beta value of 0.34. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for XFOR is 117.21M, and currently, short sellers hold a 11.04% ratio of that float. The average trading volume of XFOR on December 09, 2024 was 2.44M shares.
XFOR) stock’s latest price update
X4 Pharmaceuticals Inc (NASDAQ: XFOR) has seen a rise in its stock price by 30.29 in relation to its previous close of 0.40. However, the company has experienced a 40.16% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-03 that BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on December 2, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 396,824 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
Analysts’ Opinion of XFOR
Many brokerage firms have already submitted their reports for XFOR stocks, with B. Riley Securities repeating the rating for XFOR by listing it as a “Neutral.” The predicted price for XFOR in the upcoming period, according to B. Riley Securities is $1 based on the research report published on December 12, 2023 of the previous year 2023.
B. Riley Securities, on the other hand, stated in their research note that they expect to see XFOR reach a price target of $3. The rating they have provided for XFOR stocks is “Buy” according to the report published on August 30th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to XFOR, setting the target price at $3 in the report published on December 22nd of the previous year.
XFOR Trading at 6.51% from the 50-Day Moving Average
After a stumble in the market that brought XFOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.50% of loss for the given period.
Volatility was left at 16.62%, however, over the last 30 days, the volatility rate increased by 9.29%, as shares sank -18.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.87% lower at present.
During the last 5 trading sessions, XFOR rose by +36.17%, which changed the moving average for the period of 200-days by -46.11% in comparison to the 20-day moving average, which settled at $0.4009. In addition, X4 Pharmaceuticals Inc saw -37.98% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XFOR starting from Ragan Paula, who sale 31,897 shares at the price of $0.39 back on Nov 15 ’24. After this action, Ragan Paula now owns 993,919 shares of X4 Pharmaceuticals Inc, valued at $12,583 using the latest closing price.
Ragan Paula, the Officer of X4 Pharmaceuticals Inc, proposed sale 31,897 shares at $0.41 during a trade that took place back on Nov 15 ’24, which means that Ragan Paula is holding shares at $13,078 based on the most recent closing price.
Stock Fundamentals for XFOR
Current profitability levels for the company are sitting at:
- -6.19 for the present operating margin
- 0.85 for the gross margin
The net margin for X4 Pharmaceuticals Inc stands at -4.01. The total capital return value is set at -0.17. Equity return is now at value -26.35, with -9.54 for asset returns.
Based on X4 Pharmaceuticals Inc (XFOR), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at -1.64. The debt to equity ratio resting at 1.28. The interest coverage ratio of the stock is -3.1.
Currently, EBITDA for the company is -107.52 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 16.78. The receivables turnover for the company is -0.93for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.89.
Conclusion
To put it simply, X4 Pharmaceuticals Inc (XFOR) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
